PMID- 23587351
OWN - NLM
STAT- MEDLINE
DCOM- 20140122
LR  - 20161031
IS  - 2213-3941 (Electronic)
IS  - 0003-4266 (Linking)
VI  - 74
IP  - 2
DP  - 2013 May
TI  - [New perspectives for metformin in cancer therapy].
PG  - 130-6
LID - S0003-4266(13)00020-6 [pii]
LID - 10.1016/j.ando.2013.02.002 [doi]
AB  - Cancer and type II diabetes are two diseases that appear to be associated. In 
      fact, diabetes increases the incidence of several cancers (colon, endometrium, 
      rectum and breast). Retrospective epidemiological studies show that metformin, a 
      drug commonly used in type II diabetes, has antitumor properties. Therefore, many 
      experimental studies (in vivo and in vitro) have been initiated in recent years 
      to understand the cellular and molecular mechanisms that may explain the 
      protective effects of metformin against cancer. Two main mode of action have been 
      proposed. The first, indirect, involves the decrease of insulinemia. The second, 
      via a direct action on cells, results in the regulation of the activated AMPK 
      kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway, which plays a central 
      role in many cellular processes such as energy metabolism, protein synthesis, 
      autophagy and apoptosis. Here, we review recent results concerning the antitumor 
      action of metformin: epidemiological, metabolic, cellular and molecular levels. 
      Ongoing experimental and clinical trials should help us better understand the 
      mechanisms of action of metformin and allow us to determine whether the drug can 
      be used in the treatment of cancer.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
FAU - Loubiere, Camille
AU  - Loubiere C
AD  - Inserm U1065, centre mediterraneen de medecine moleculaire, equipe << 
      physiopathologie cellulaire et moleculaire de l'obesite et du diabete >>, 06204 
      Nice, France.
FAU - Dirat, Beatrice
AU  - Dirat B
FAU - Tanti, Jean-Francois
AU  - Tanti JF
FAU - Bost, Frederic
AU  - Bost F
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
TT  - Metformine et cancer : de nouvelles perspectives pour un ancien medicament.
DEP - 20130412
PL  - France
TA  - Ann Endocrinol (Paris)
JT  - Annales d'endocrinologie
JID - 0116744
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Drug Repositioning/methods/trends
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incidence
MH  - Metformin/*therapeutic use
MH  - Neoplasms/*drug therapy/epidemiology/etiology
EDAT- 2013/04/17 06:00
MHDA- 2014/01/23 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/17 06:00 [entrez]
PHST- 2013/04/17 06:00 [pubmed]
PHST- 2014/01/23 06:00 [medline]
AID - S0003-4266(13)00020-6 [pii]
AID - 10.1016/j.ando.2013.02.002 [doi]
PST - ppublish
SO  - Ann Endocrinol (Paris). 2013 May;74(2):130-6. doi: 10.1016/j.ando.2013.02.002. 
      Epub 2013 Apr 12.